Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
Ημερομηνία
2020Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Background: European data indicate that systemic sclerosis (SSc)-related death rates are increasing, thus raising concerns about SSc's optimal management. Herein, we describe current treatment modalities and drug survival in a real-life SSc cohort. Methods: Details on immunosuppressive/antiproliferative (methotrexate, mycophenolate, cyclophosphamide, azathioprine, rituximab, tocilizumab) and vasoactive agent [(endothelin receptor antagonists (ERAs), sildenafil, iloprost, and calcium channel blockers (CCB)] administration during the disease course (11.8 ± 8.4 years, mean + SD) of 497 consecutive patients examined between 2016 and 2018 were retrospectively recorded. Drug survival was assessed by Kaplan-Meier analysis. Results: Methotrexate was the most frequently administered immunosuppressive/antiproliferative agent (53% of patients), followed by cyclophosphamide (26%), mycophenolate (12%), and azathioprine (11%). Regarding vasoactive agents, CCB had been ever administered in 68%, ERAs in 38%, iloprost in 7%, and sildenafil in 7% of patients; 23% of patients with pulmonary fibrosis had never received immunosuppressive/antiproliferative agents, 33% of those with digital ulcers had never received ERAs, iloprost, or sildenafil, whereas 19% of all patients had never received either immunosuppressive/antiproliferative or other than CCB vasoactive agents. Survival rates of methotrexate, cyclophosphamide, and mycophenolate differed significantly, being 84/75%, 59/43%, and 74/63% at 12/24 months, respectively, with inefficacy being the most frequent discontinuation cause. Conversely, CCB, ERAs, and sildenafil had high and comparable retention rates of 97/91%, 88/86%, and 80/80%, respectively. Conclusions: Existing therapeutic limitations indicate that more evidence-based treatment is warranted for successful management of SSc. Vasculopathy seems to be managed more rigorously, but the low retention rates of immunosuppressive/antiproliferative drugs suggest that effective and targeted disease-modifying agents are warranted. © 2020 The Author(s).
Collections
Related items
Showing items related by title, author, creator and subject.
-
Skeletal muscle relaxants in anaesthesiology
Benakis, A.; Plessas, C. T.; Plessas, S. T. (1999)During the 16th century, European explorers found that the Indians along the Amazon and Orinoco Rivers were using an arrow poison, named curare, that produced death by skeletal paralysis. Curare is one of several different ... -
Chios mastic gum: A plant-produced resin exhibiting numerous diverse pharmaceutical and biomedical prοperties
Dimas, K. S.; Pantazis, P.; Ramanujam, R. (2012)Chios mastic gum (CMG) is a resin produced by the plant Pistacia lentiscus var. chia. CMG is used to extract the mastic gum essential oil (MGO). CMG and MGO consist of nearly 70 constituents and have demonstrated numerous ... -
Drug-induced endocrinopathies and diabetes: A combo-endocrinology overview
Diamanti-Kandarakis E., Duntas L., Kanakis G.A., Kandaraki E., Karavitaki N., Kassi E., Livadas S., Mastorakos G., Migdalis I., Miras A.D., Nader S., Papalou O., Poladian R., Popovic V., Rachoń D., Tigas S., Tsigos C., Tsilchorozidou T., Tzotzas T., Bargiota A., Pfeifer M., on behalf of COMBO ENDO TEAM: 2018 (2019)In the currently overwhelming era of polypharmacy, the balance of the dynamic and delicate endocrine system can easily be disturbed by interfering pharmaceutical agents like medications. Drugs can cause endocrine abnormalities ...